文献速递银屑病与炎症性皮肤病

靶向IL-17受体的脂质体球形核酸外用治疗银屑病

Targeting the IL-17 Receptor Using Liposomal Spherical Nucleic Acids as Topical Therapy for Psoriasis.
PubMed 文献 · J Invest Dermatol · 2019-08-15

该研究开发了靶向IL-17A受体基因的脂质体球形核酸(L-SNA),在咪喹莫特诱导的银屑病样小鼠皮肤中局部外用后,临床、组织学和转录水平均逆转银屑病发展;人IL17RA L-SNA可穿透三维培养和正常人皮肤外植体并敲低靶基因,在银屑病三维筏模型中也显著降低IL17RA及IL-17诱导基因表达。

要点

  • 局部外用Il17ra L-SNA可逆转小鼠银屑病样皮肤改变。
  • 人IL17RA L-SNA能穿透人皮肤并敲低IL17RA mRNA。
  • 靶向抑制IL17RA是银屑病潜在外用治疗新策略。

核心结论

  • 靶向抑制IL17RA是银屑病有前景的新型外用治疗策略。

研究设计与样本

  • 研究在咪喹莫特诱导的银屑病样小鼠皮肤、人三维培养、正常人皮肤外植体和银屑病三维筏模型中评估L-SNA。

主要发现

  • Il17ra L-SNA使改良PASI较对照降低74%,表皮厚度减少56%。
  • Il17ra L-SNA使Il17ra蛋白表达降低75%,并显著降低Defb4、Il17c、S100a7、Pi3、Krt16和Tnfa的mRNA表达。
  • 人IL17RA L-SNA穿透三维培养和正常人皮肤外植体,分别敲低IL17RA mRNA 63%和66%。
  • 在银屑病三维筏局部应用后,抗人IL17RA L-SNA使IL17RA表达降低72%,IL17C降低85%,DEFB4降低83%,TNFA降低77%,PI3降低65%(均P < 0.001)。

临床怎么用

  • 提示局部外用靶向IL17RA的L-SNA可能成为银屑病治疗选择,但尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The activation of T helper 17 signaling plays a critical role in psoriasis pathogenesis, and systemically-administered IL-17 inhibitors are highly effective therapy for moderate-to-severe disease. We generated topically-delivered gene-regulating nanoconstructs, comprised of spherically-arrayed antisense DNA (liposomal spherical nucleic acids [L-SNAs]), which are able to penetrate human skin to knock down cutaneous gene targets. Topically-applied L-SNAs targeting the gene encoding the mouse IL-17A receptor (Il17ra) reversed the development of psoriasis clinically, histologically, and transcriptionally in imiquimod-treated psoriasis-like mouse skin. Il17ra L-SNAs reduced the modified PASI by 74% versus controls and decreased epidermal thickness by 56%. Il17ra L-SNA reduced Il17ra protein expression by 75% and significantly decreased the mRNA expression of psoriasis markers, including Defb4, Il17c, S100a7, Pi3, Krt16, and Tnfa versus scrambled spherical nucleic acid (Scr SNA) controls. A human IL17RA L-SNA penetrates 3-dimensional cultures and normal human explants to knock down IL17RA mRNA by 63% and 66%, respectively. After topical application to psoriatic 3-dimensional rafts, anti-human IL17RA L-SNAs reduced the expression of IL17RA (by 72%) and the IL-17-induced genes IL17C (by 85%), DEFB4 (by 83%), TNFA (by 77%), and PI3 (by 65%) versus scrambled L-SNA and vehicle controls (all P < 0.001). Taken together, these data suggest that targeted suppression of IL17RA is a promising new topical treatment strategy for psoriasis.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Liu H, Kang RS, Bagnowski K, et al. Targeting the IL-17 Receptor Using Liposomal Spherical Nucleic Acids as Topical Therapy for Psoriasis. J Invest Dermatol. 2019. PMID: 31421125. doi:10.1016/j.jid.2019.06.146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。